Serina Therapeutics, Inc.
In the quarter to June 2026, revenue grew 2,500.0%, EPS grew 16.7% and free cash flow fell 76.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SER
Serina Therapeutics, Inc. (SER) Piotroski F-score
Serina Therapeutics, Inc.'s Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, up from 1 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | 1.00 |
| FY2024 | 1 | (5.00) |
| FY2023 | 6 | 5.00 |
| FY2022 | 1 | 0.00 |
| FY2021 | 1 | (1.00) |
| FY2020 | 2 | (1.00) |
| FY2019 | 3 | 1.00 |
| FY2018 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (280.54%) | (142.00%) | Fail | 0 |
| Positive operating cash flow | (17.95m) | (17.14m) | Fail | 0 |
| Rising return on assets | (280.54%) | (142.00%) | Fail | 0 |
| Cash flow above net income | 1.23m | (6.00m) | Pass | 1 |
| Falling long-term leverage | 0.43 | 0.00 | Fail | 0 |
| Rising current ratio | 1.71 | 2.40 | Fail | 0 |
| No new shares issued | 10,190,000 | 7,359,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.02 | 0.01 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INMB INmune Bio, Inc. compare | 4 |
| IBIO iBio, Inc. compare | 4 |
| IMA ImageneBio, Inc. compare | 3 |
| SER Serina Therapeutics, Inc. | 2 |
| CLNN Clene Inc. compare | 2 |
| KLRS Kalaris Therapeutics Inc. compare | — |
| ANVS Annovis Bio, Inc. compare | — |
| ALDX Aldeyra Therapeutics, Inc. compare | — |
| TVGN Tevogen Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover